The discovery of the BCR-ABL fusion gene as the hallmark of chronic myelogenous leukemia (CML) and the development of the BCR-ABL inhibitor imatinib marked a pivotal moment in drug development. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.